Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Research output: Contribution to journal › Journal article › Research › peer-review
Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.
| Original language | English |
|---|---|
| Journal | Current Opinion in Pharmacology |
| Volume | 4 |
| Issue number | 6 |
| Pages (from-to) | 589-96 |
| Number of pages | 7 |
| ISSN | 1471-4892 |
| DOIs | |
| Publication status | Published - 2004 |
Bibliographical note
Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Great Britain; Humans; Peptide Fragments; Protease Inhibitors; Protein Precursors
ID: 8417324